HER2 PET/CT超敏检测副乳腺癌骨转移一例
本病例报告描述一名52岁右侧腋窝HER2阳性副乳腺癌女性,18F-FDG与68Ga-HER2 affibody PET/CT均显示腋窝病灶高摄取;经6周期TCbHP方案治疗后腋窝病灶明显缩小。
要点
- HER2 PET/CT较骨扫描和18F-FDG PET/CT更敏感地检出HER2阳性骨转移。
- HER2 PET/CT有助于HER2阳性副乳腺癌的精准分期。
- HER2 PET/CT可指导HER2靶向治疗决策。
核心结论
- HER2 PET/CT能更敏感地检测HER2阳性病灶,从而实现精准分期并指导HER2靶向治疗。
主要发现
- 18F-FDG和HER2 PET/CT均显示多个腋窝病灶高摄取。
- 18F-FDG PET/CT仅检出少数骨病灶伴轻度示踪剂摄取。
- 经6周期TCbHP方案治疗后腋窝病灶明显缩小。
临床怎么用
- 对HER2阳性副乳腺癌患者,HER2 PET/CT可用于更敏感地检出骨转移并辅助精准分期。
- HER2 PET/CT结果可帮助筛选适合HER2靶向治疗的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We presented the imaging findings of 18 F-FDG and 68 Ga-HER2 affibody PET/CT in a 52-year-old woman with HER2-positive accessory breast cancer in the right axilla. 18 F-FDG and HER2 PET/CT showed avid uptake of multiple axillary lesions. HER2 PET/CT identified extensive bone metastases with intense uptake, while the ⁹⁹ᵐTc-MDP whole bone scan was negative, and only a few bone lesions with mild tracer uptake were detected by 18 F-FDG PET/CT. Following 6 cycles of the TCbHP regimen, the axillary lesions markedly reduced. This case demonstrates that HER2 PET/CT enables more sensitive detection of HER2-positive lesions, thereby allowing for precise staging and guiding HER2-targeted therapy.
引用
- Yang L, Zhu D, Song S, et al. Ultra-Sensitive Detection of Bone Metastasis From Accessory Breast Cancer Using HER2 PET/CT: A Case Report. Clin Nucl Med. 2026. PMID: 41553239. doi:10.1097/RLU.0000000000006305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。